

# Palmyramide A, a Cyclic Depsipeptide from a Palmyra Atoll Collection of the Marine Cyanobacterium *Lyngbya majuscula*

*Masatoshi Taniguchi, Joshawna K. Nunnery, Niclas Engene, Eduardo Esquenazi, Tara Byrum,*

*Pieter C. Dorrestein, and William H. Gerwick*

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego,

La Jolla, CA 92093 USA

## **Supporting Information**

S1:  $^1\text{H}$  NMR spectrum of palmyramide A (600 MHz,  $\text{CDCl}_3$ )

S2:  $^{13}\text{C}$  NMR spectrum of palmyramide A (150 MHz,  $\text{CDCl}_3$ )

S3: COSY spectrum of palmyramide A ( $\text{CDCl}_3$ )

S4: TOCSY spectrum of palmyramide A ( $\text{CDCl}_3$ )


S5: HSQC spectrum of palmyramide A ( $\text{CDCl}_3$ )

S6: HMBC spectrum of palmyramide A ( $\text{CDCl}_3$ )


S7: Selected HMBC correlations of palmyramide A (**1**).

S8: HPLC trace of purified palmyramide A with diode array detection and electrospray ionization mass spectrometry detection (**1**).


S1: <sup>1</sup>H NMR spectrum of palmyramide A (600 MHz, CDCl<sub>3</sub>)




S2:  $^{13}\text{C}$  NMR spectrum of palmyramide A (150 MHz,  $\text{CDCl}_3$ )




S3: COSY spectrum of palmyramide A (CDCl<sub>3</sub>)



S4: TOCSY spectrum of palmyramide A (CDCl<sub>3</sub>)



S5: HSQC spectrum of palmyramide A (CDCl<sub>3</sub>)



S6: HMBC spectrum of palmyramide A (CDCl<sub>3</sub>)




Figure S7: Selected HMBC correlations of palmyramide A (**1**).







Figure S8: HPLC trace of purified palmyramide A with diode array detection and electrospray ionization mass spectrometry detection (1).

D:\Data\Jo\100509\_Palmyramide\_A\_7

10/5/2009 12:32:08 PM



100509\_Palmyramide\_A\_7 #255-291 RT: 6.69-7.53 AV: 37 NL: 1.61E7  
T: + c ESI Full ms [ 150.00-2000.00]



Column: Hewlett-Packard Lichrospher 100 RP-18; 5  $\mu$ m, 125 x 4 mm; 79925OD-564

Conditions: 0.7 mL/min isocratic 70:30 CH<sub>3</sub>CN:H<sub>2</sub>O

Injection: 10  $\mu$ L injection of 100  $\mu$ g/mL solution of palmyramide A in 100% CH<sub>3</sub>CN (peak at 1.72 min retention in the PDA trace represents the 100% CH<sub>3</sub>CN elution peak, or one column volume)

$m/z$ : 672.28 = [M+H]<sup>+</sup>; 694.45 = [M+Na]<sup>+</sup>; 1365.18 = [2M+Na]<sup>+</sup>